Building on these advances, a MYD88-targeted immunochemotherapy strategy has been proposed, integrating BTK inhibitors with conventional immunochemotherapy to specifically focus on MYD88-mutant DLBCL. Here, BTK is linked to diffuse large B-cell lymphoma.